tbuckley/cabot-search huggingface dataset:
Cardiac Arrest During Trichlorethylene Anaesthesia
Authors: W. Norris, P. Stuart
Journal: BMJ (1957)

PATIENTS MBzcAsHJou1^Aoften they have failed to appoint independent observers even of behaviour, and less still have they made thorough investigations into the psychological state of their patients.Our experience, we think, emphasizes the importance of design in a trial of this kind and draws attention to the paucity of evidence on which claims are made about drugs alleged to allay apprehension.So far as overt conduct is concerned, we are of the opinion, from our present findings, that for children 6 years of age and over preliminary sedation before dental ex- tractions undertaken with a general anaesthetic is usually unnecessary.Below this age any method of improving behaviour would be an advantage.Methylpentynol, buto- barbitone, and chlorpromazine scarcely provide the answer, at least in the doses we used, and there is the risk that with higher doses side-effects might be manifest.Moreover, many " elixirs " are unpalatable, and often their administra- tion may itself contribute to loss of confidence. SummaryThe case for the pre-operative sedation of children before general anaesthesia for dental operations as out- patients is examined.The problem of assessing the effect of a pre-operative sedative drug is considered.A method of solving it by using a behaviour-grading process was evolved and tested.Methylpentynol, butobarbitone, and chlorpromazine were selected as potentially useful premedicant drugs.Using the " double blind " technique and our method of assessment, a pilot trial and a major trial of these three drugs were carried out within the framework of the routine dental gas session in Guy's Hospital.A very marked difference was shown between the patterns of behaviour of the older and the younger children.None of the three drugs could be distinguished from a placebo by their effect on the behaviour of the children about to be anaesthetized.Possible explanations of this negative result are discussed.We thank Mr. R. E. Rix and Mr. K. E. Pringle and their assistants for their courtesy in allowing this investigation to be undertaken at their dental extraction sessions, and also the sisters and nursing staff concerned for the
Abstract 15370: Albuminuria is Associated With Greater Risk of Lower Limb Amputation in Diabetic Patients With Peripheral Artery Disease
Authors: Jung-Im Shin, Morgan Grams, Josef Coresh, Alex Chang, Kuni Matsushita
Journal: Circulation (2017)

Introduction: Prior studies have found that albuminuria is associated with increased risk of peripheral artery disease (PAD). However, its association with future risk of lower limb amputation in p...
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Authors: Namrata S Chandhok, Scott F. Huntington, Iris Isufi, Lohith Gowda, Mina L Xu, Noffar Bar, Stuart Seropian, Francine M. Foss
Journal: Blood (2019)
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Authors: Surbhi Sidana, David L Murray, Surendra Dasari, Ronald S. Go, Maria Alice Willrich, Melissa Snyder, Mindy Kohlhagen, John A. Lust, Eli Muchtar, Taxiarchis Kourelis, Shaji K. Kumar, Angela Dispenzieri, Morie A. Gertz
Journal: Blood (2019)
Patient-derived organoid models of metastatic colorectal cancer to study response to PIK3CA inhibitors
Authors: J.D. Barros Silva, K. Wanigasooriya, H. Bermingham, S. Patel, R. Hoare, A. Stodolna, O. Pickles, C. Bryer, C. Whalley, A. Beggs
Journal: Annals of Oncology (2019)
Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Authors: Paolo Strati, Sudhakar Tummala, Loretta J. Nastoupil, Jason R. Westin, Luis Fayad, Sairah Ahmed, Nathan H. Fowler, F. B. Hagemeister, Hun Ju Lee, Swaminathan P. Iyer, Ranjit Nair, Simrit Parmar, Maria Alma Rodriguez, Felipe Samaniego, Raphael Eric Steiner, Michael L. Wang, Chelsea Camille Pinnix, Sherry Adkins, Catherine M. Claussen, Charles Martinez, Misha Hawkins, Nicole Johnson, Shirley George, Sattva S Neelapu, Linda Chi
Journal: Blood (2019)
Pancreatic endoscopic retrograde cholangiopancreatography (ERCP)
Authors: J.-M. Dumonceau, A. Vonlaufen
Journal: Endoscopy (2007)

We review developments in five areas of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) and management of pancreatic tumors during the period September 2005 - August 2006. First, in the management of painful chronic pancreatitis, the use of multiple plastic stents for aggressive dilation of strictures located in the head of the pancreas has been put forward to resolve two significant issues associated with current techniques, i. e., the requirement for numerous ERCPs for stent exchange and the high relapse rate after stent removal. We then discuss the identification of protective factors against post-ERCP pancreatitis following pancreatic sphincterotomy. Next, bearing in mind the prospect of increasing use of neoadjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma, new evidence supporting the systematic use of self-expandable metal biliary stents before cancer staging is presented and critically considered. A French study on the natural history of intraductal papillary mucinous neoplasms, which reinforces the current recommendation not to operate on all of these patients, is also discussed. Finally two centers with a high volume of cases have reported their experience with the drainage of pancreatic fluid collections with or without endosonography (EUS) guidance. It appears that EUS has extended the applicability of endoscopic drainage but, for collections amenable to conventional endoscopic techniques, it remains uncertain whether safety and effectiveness are improved when EUS guidance is used. Technical requisites for long-term success of drainage have been confirmed: multiple, double-pigtail stents should be inserted for a minimum of 6 weeks. It has also become evident that training in this technique is insufficient at many centers.
Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre
Authors: RAM V Nampoothiri, Arjun Law, Wilson Lam, Zeyad Al-Shaibani, David Loach, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Rajat Kumar, Jonas Mattsson, Jeffrey H. Lipton, Auro Viswabandya
Journal: Blood (2019)
Placing Value on End-of-Life Care—Is It Time for a New Taxonomy?
Authors: May Hua, Hannah Wunsch
Journal: JAMA Network Open (2019)

Deepshikha Charan Ashana, MD, MBA; Xiaoxue Chen, MPH; Abiy Agiro, PhD; Gayathri Sridhar, MBBS, MPH, PhD; Ann Nguyen, PharmD; John Barron, PharmD; Kevin Haynes, PharmD; Michael Fisch, MD; David Debono, MD; Scott D. Halpern, MD, PhD; Michael O. Harhay, PhD
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Authors: Angelo Fama, Peter Martin, Cristine Allmer, Carla Casulo, Jonathon B. Cohen, Umar Farooq, Andrew L. Feldman, Jonathan W. Friedberg, Thomas M. Habermann, David L. Jaye, Brad S. Kahl, Brian K. Link, Izidore S. Lossos, Matthew J. Maurer, Loretta J. Nastoupil, Sarah C. Rutherford, Susan L Slager, Carrie A. Thompson, Christopher R. Flowers, James R. Cerhan
Journal: Blood (2019)
Investigating Antibiotic Exposure and Risk of Severe Acute Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Razan Mohty, Remy Dulery, Giorgia Battipaglia, Eolia Brissot, Clemence Mediavilla, Simona Sestili, Tounes Ledraa, Béatrice Gaugler, Agnès Bonnin, Mohamad Mohty, Florent Malard
Journal: Blood (2019)
Tuberculosis incidence among migrants according to migrant status: a cohort study, Denmark, 1993 to 2015
Authors: Kristina Langholz Kristensen, Troels Lillebaek, Joergen Holm Petersen, Sally Hargreaves, Laura B Nellums, Jon S Friedland, Peter Henrik Andersen, Pernille Ravn, Marie Norredam
Journal: Eurosurveillance (2019)

BackgroundMigrants account for the majority of tuberculosis (TB) cases in low-incidence countries in western Europe. TB incidence among migrants might be influenced by patterns of migration, but this is not well understood.AimTo investigate differences in TB risk across migrant groups according to migrant status and region of origin.MethodsThis prospective cohort study included migrants ≥ 18 years of age who obtained residency in Denmark between 1 January 1993 and 31 December 2015, matched 1:6 to Danish-born individuals. Migrants were grouped according to legal status of residency and region of origin. Incidence rates (IR) and incidence rate ratios (IRR) were estimated by Poisson regression.ResultsThe cohort included 142,314 migrants. Migrants had significantly higher TB incidence (IR: 120/100,000 person-years (PY); 95% confidence interval (CI): 115-126) than Danish-born individuals (IR: 4/100,000 PY; 95% CI: 3-4). The IRR was significantly higher in all migrant groups compared with Danish-born (p < 0.01). A particularly higher risk was seen among family-reunified to refugees (IRR: 61.8; 95% CI: 52.7-72.4), quota refugees (IRR: 46.0; 95% CI: 36.6-57.6) and former asylum seekers (IRR: 45.3; 95% CI: 40.2-51.1), whereas lower risk was seen among family-reunified to Danish/Nordic citizens (IRR 15.8; 95% CI: 13.6-18.4) and family-reunified to immigrants (IRR: 16.9; 95% CI: 13.5-21.3).DiscussionAll migrants had higher TB risk compared with the Danish-born population. While screening programmes focus mostly on asylum seekers, other migrant groups with high risk of TB are missed. Awareness of TB risk in all high-risk groups should be strengthened and screening programmes should be optimised.
Costs and outcomes associated with hospitalizations for venous thromboembolic disease in patients with malignant neoplasm
Authors: S. Weidner, M. B. Schilling, C. Parks
Journal: Journal of Clinical Oncology (2009)

6590 Background: Venous thromboembolic disease (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common occurrence in oncology, as patients with cancer have a greatly increased risk of VTE. Costs of VTE treatment are significant, including direct costs (expenditures for procedures, tests, medications, and services), indirect morbidity costs (lost income from work due to the condition or disability), and indirect mortality costs (lost income due to early mortality). Costs associated with VTE contribute to the overall cost of cancer care, however studies that examine the cost of care for oncology patients that develop VTEs are limited. Methods: A retrospective cohort study identified patients with cancer hospitalized during January 2006 through May 2008 using a large US healthcare database (&gt;342 inpatient facilities across all US regions, ∼ 11 million patients and &gt; 300 million charge- detail records). Patients with an ICD-9-CM code for malignant neoplasm (140.xx-208.xx) in combination with DVT or PE (415.11,415.19, 453.4,453.41,453.42) were included. Using Aspen's charge cost model, the hospital's clinical, utilization and billing, and cost accounting records healthcare cost, LOS, and mortality rates associated with these hospitalizations were calculated. Results: Data from 74 facilities with a mean bed size of 349 was utilized. A total of 77% of these facilities were not classified as teaching hospitals. Overall 1136 inpatients were identified with a diagnosis of malignant neoplasm and either DVT or PE. Table 1 shows the results. Conclusions: DVT/PE contributes to the cost of cancer treatment and is a considerable cost driver. Additionally, human costs are high. Aggressive practices to prevent these complications can result in a lower healthcare burden. In an era of restricted resources and value based purchasing, these data can be used to prioritize resource utilization. [Table: see text] [Table: see text]
A-to-I–edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis
Authors: Xiaoyan Xu, Yumeng Wang, Kamalika Mojumdar, Zhicheng Zhou, Kang Jin Jeong, Lingegowda S. Mangala, Shuangxing Yu, Yiu Huen Tsang, Cristian Rodriguez-Aguayo, Yiling Lu, Gabriel Lopez-Berestein, Anil K. Sood, Gordon B. Mills, Han Liang
Journal: Journal of Clinical Investigation (2019)

Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics.
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Authors: Selina M. Luger, Zhuoxin Sun, Sanam Loghavi, Hillard M Lazarus, Jacob M. Rowe, Martin S. Tallman, Keith W. Pratz, Mark Litzow
Journal: Blood (2019)
Targeting CD38high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells
Authors: Emma Nolan, Arwen Stikvoort, Mark Gurney, Nutsa Burduli, Lucy Kirkham-McCarthy, John Daly, Niels W. C. J. Van De Donk, Tuna Mutis, Subhashis Sarkar, Michael E O'Dwyer
Journal: Blood (2019)
Growth Factor-Dependent Activation of a MYC-Induced Latent AML Program in Human Hematopoietic Cells
Authors: Elizabeth Bulaeva, Davide Pellacani, Naoto Nakamichi, Philip Beer, Colin Hammond, Alireza Lorzadeh, Michelle Moksa, Annaick Carles, Misha Bilenky, Sylvain Lefort, Jeremy Shu, Brian T. Wilhelm, Andrew P. Weng, Martin Hirst, Connie J. Eaves
Journal: Blood (2019)
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)
Authors: Jose C Villasboas, Craig B. Reeder, Han W. Tun, Nancy L Bartlett, Elad Sharon, Betsy Laplant, Alex A Adjei, Justin Kline, Francisco J. Hernandez-Ilizaliturri, Farrukh T. Awan, Sumana Devata, Aleksandr Lazaryan, Lawrence E Morris, Stephen M Ansell, Catherine Diefenbach
Journal: Blood (2019)
ATIM-11. TUMOR-INFILTRATING LYMPHOCYTES EXPRESSING ANTI-PD-1 ANTIBODY EXHIBIT A PROMISING EFFICACY AND SURVIVAL BENEFIT IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Authors: Chao Tang, Zhi Zhang, Di Chen, Kai Ji, Chunxia Ji, Xiao Liu, Ling Chen, Qiqi Lu, Wen Chu, Wen Qin, Fei Xu, Hua Jin, Qi Qian, Yu Yao, Liang Zhou
Journal: Neuro-Oncology (2019)

Abstract Adoptive cell therapies utilizing autologous tumor-infiltrating lymphocytes (TIL) have been demonstrated to be safe and promising in anti-tumor activities; However, their efficiency was still low in treating glioblastoma multiforme (GBM) because of immunosuppression microenvironment. In this study, we proposed a new strategy to enhance the anti-tumor immune response by using modified TIL expressing anti-PD-1 antibody (anti-PD1-TIL), which could reverse immunosuppression in tumor microenviroment. From April 2017 to April 2018，a total of 8 patients with recurrent GBM were enrolled and received more than one cycles of anti-PD1-TIL immunotherapy after surgery and chemotherapy with a median follow-up of 20 months. The anti-PD1-TIL immunotherapy was well tolerated. Two patients suffered grade 1 and 2 adverse events, including fatigue, mucosal/cutaneous toxicities. The median overall survival time was 16.1（95% CL: 15.4–16.7）months. By iRANO criteria, one patient experienced a partial response (PR), and three patients experienced stable disease (SD) after anti-PD-1-TIL immunotherapy. Genomic analysis by whole exome sequencing revealed an enrichment of MUC12 mutation in responders (p&lt; 0.01), and an enrichment of TMEM125 (p&lt; 0.01) and HIST2H3A/C amplification (p&lt; 0.05) associated with immunosuppressive signature in non-responders. Taken together, the anti-PD1-TIL immunotherapy is a safe and promising strategy with durable efficacy to treat patients with recurrent GBM. Clinicaltrials.gov identifier: NCT 03347097.
RARE-26. WHOLE GENOME SEQUENCING OF AN OSSEOUS METASTASIS DURING CHECKPOINT-CONTROLLED INTRACRANIAL GLIOBLASTOMA REVEALS NEW INSIGHTS INTO POTENTIAL MECHANISMS OF IMMUNE ESCAPE
Authors: Malte Mohme, Cecile Maire, Simon Schliffke, Simon Joosse, Malik Alawi, Katrin Lamszus, Manfred Westphal
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) has a devastating prognosis and recent advances in the treatment of a variety of cancer entities, e.g. through checkpoint inhibition, could so far not be translated into improved outcome in newly-diagnosed GBM. Characterizing rare cases of peripheral metastases which succeeded in overcoming immune control, can help to understand the mechanisms of immune escape. Here we describe the first reported case of a detailed genetic and immunological characterization of a peripheral bone metastasis from a GBM which was controlled intracranially by anti-PD1 checkpoint inhibition We performed whole genome sequencing (WGS) of the primary- and recurrent tumor, as well as the bone metastasis. Genomic data was analyzed for copy number variations and mutational profiles. In addition, immune monitoring with flow cytometric phenotyping and next-generation sequencing of the peripheral T-cell repertoire was used. A 70-year old patient developed multiple osseous metastases in the spine, while his IDHwt GBM recurrence was immunologically controlled with checkpoint inhibition. Biopsy confirmed peripheral GBM metastases. Immunophenotyping reflected the effective activation of the peripheral T-cell response, with, however, simultaneous upregulation of regulatory T-cells during disease progression. WGS sequencing demonstrated a distinct molecular profile of the GBM metastasis, with amplifications in chromosome 3 and 9, as well as genomic loss on chromosomes 4, 10 and 11. The peripheral metastasis was distinguished by mutations in mismatch repair genes, such as MSH4 and MLH1, associated with a hypermutated phenotype. Among the mutated genes we found potential candidates involved in immune escape of circulating tumor cells. This case represents a unique opportunity to analyze potential mechanisms of GBM-mediated immune escape during immune activation with anti-PD1 checkpoint therapy. It highlights the fact, that although an effective, disinhibited immune response can control the cranial GBM disease, hypermutated tumor clones can evade the tumor-specific T-cell response and disseminate to distant organs.
CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Authors: Hany Elmariah, Syeda Mahrukh Hussnain Naqvi, Jongphil Kim, Taiga Nishihori, Asmita Mishra, Lia Perez, Hien D. Liu, Farhad Khimani, Michael Nieder, Joseph Pidala, Nelli Bejanyan
Journal: Blood (2019)
Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017
Authors: Kira Seiger, Arash Mostaghimi, Ann W. Silk, Chrysalyne D. Schmults, Emily Stamell Ruiz
Journal: JAMA Oncology (2019)

This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.
The Road to Day 0: Identification of Barriers from HLA Typing to Transplantation in the Era of Haploidentical Grafts and Post-Transplant Cyclophosphamide
Authors: Perla R. Colunga Pedraza, Andrés Gómez-De León, Mónica Bustillos Muñoz, Diana E Garcia-Camarillo, Rosario Salazar Riojas, Leslie Silva López, Olga Graciela Cantu Rodriguez, Cesar Homero Gutierrez-Aguirre, David Gomez-Almaguer
Journal: Blood (2019)
Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy
Authors: John Markham, Satwica Yerneni, Georgina L Ryland, Andrew Fellowes, Ella Thompson, Stephen Fox, David Alan Westerman, Michael Dickinson, Anthony Papenfuss, Piers Blombery
Journal: Blood (2019)
Myeloid Neoplasms with t(12;22)(p13;q12) and MN1 Ectopia Are Refractory to Chemotherapy and Can Benefit from Hematopoietic Stem Cell Transplantation
Authors: Tong Wang, Xue Chen, Shuang Hui, Jingbo Ni, Ying Yin, Wei Cao, Yan Zhang, Xinyu Wang, Xiaoli Ma, Panxiang Cao, Mingyue Liu, Kylan N. Chen, Fang Wang, Yang Zhang, Daijing Nie, Lili Yuan, Hongxing Liu
Journal: Blood (2019)
Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Authors: Sathya Muralidhar, Anastasia Filia, Jérémie Nsengimana, Joanna Poźniak, Sally J. O'Shea, Joey M. Diaz, Mark Harland, Juliette A. Randerson-Moor, Jörg Reichrath, Jonathan P. Laye, Louise van der Weyden, David J. Adams, D.T. Bishop, Julia Newton-Bishop
Journal: Cancer Research (2019)

1α,25-Dihydroxyvitamin D3 signals via the vitamin D receptor (VDR). Higher serum vitamin D is associated with thinner primary melanoma and better outcome, although a causal mechanism has not been established. As patients with melanoma commonly avoid sun exposure, and consequent vitamin D deficiency might worsen outcomes, we interrogated 703 primary melanoma transcriptomes to understand the role of vitamin D-VDR signaling and replicated the findings in The Cancer Genome Atlas metastases.
Control of Hypercytokinemia in Critically Ill Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis with Plasma Exchange and Continuous Renal Replacement Therapy
Authors: Chengshuang Huang, Pei Huang, Xueqin Jiang, Hongbo Xu, Jian Lu, Runmei Tian, Ping Zhu, Yan Chen
Journal: Blood (2019)
Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies
Authors: Dietger Niederwieser, Rainer Krahl, Christoph Kahl, Hans-Heinrich Wolf, Sebastian Scholl, Michael Cross, Ute Hegenbart, Norma Peter, Christian Niederwieser, Axel Florschütz, Kolija Reifenrath, Niklas Zojer, Christian Jakob, Christian Junghanss, Herbert G. Sayer, Volker Schmidt, Sebastian Schwind, Georg Maschmeyer, Thomas Fischer, Andreas Hochhaus, Haifa Kathrin Al-Ali, Thomas Heinicke
Journal: Blood (2019)